14 KiB
| type | agent | date | status | research_question | belief_targeted |
|---|---|---|---|---|---|
| musing | vida | 2026-04-24 | active | Does GLP-1's action on VTA dopamine reward circuits suggest that addiction and obesity are primarily biological conditions — and what does this mean for Belief 2's behavioral primacy framework? | Belief 2 (80-90% of health outcomes determined by non-clinical factors) — specifically the behavioral primacy claim. If GLP-1s treat both obesity AND addiction through a shared biological mechanism, the 'behavioral' category may be substantially more biological than McGinnis-Foege implies. |
Research Musing: 2026-04-24
Session Planning
Why this direction today: Session 26 (2026-04-23) generated a new framing — the behavioral/biological dichotomy is false — and opened the GLP-1 SUD/addiction thread as a branching point. The evidence was: 33 trials underway for substance use disorders, AUD RCT evidence showing reduced self-administration and craving, VTA dopamine as the shared mechanism for both obesity and addiction.
The thread was flagged as Direction A (draft a claim on the shared biological basis of reward dysregulation conditions) vs. Direction B (wait for trial results). Today I pursue Direction A: gather the best available clinical evidence on GLP-1 for addiction, and use it to genuinely test whether the biological/behavioral boundary is where Belief 2 places it.
Keystone belief disconfirmation target: Belief 2: "Health outcomes are 80-90% determined by factors OUTSIDE medical care."
The specific disconfirmation scenario:
If GLP-1s — clinical interventions — effectively reduce alcohol consumption, opioid craving, and smoking behavior, then "behavioral" conditions may be primarily biological in substrate. The McGinnis-Foege 40-50% behavioral attribution was built when we lacked pharmacological interventions for reward-circuit conditions. If biology is the primary driver of obesity AND addiction AND potentially other "behavioral" conditions, then clinical intervention may be more determinative than Belief 2 implies.
This is the STRONGEST available challenge to Belief 2 right now. Session 26 tried it indirectly (via the VTA mechanism); today I pursue it directly by finding the best clinical evidence on GLP-1 for SUD.
What I'm searching for:
- GLP-1 (semaglutide/tirzepatide) RCT evidence for alcohol use disorder — published results 2024-2026
- GLP-1 clinical trial data for opioid use disorder — human trials
- GLP-1 for smoking cessation — any trial data
- Mechanistic evidence connecting VTA dopamine to addiction biology broadly
- Any clinician or researcher arguing that "behavioral" conditions are primarily biological — counter-evidence to Belief 2's behavioral primacy
What success looks like: A set of RCTs showing GLP-1s produce clinically meaningful reductions in addiction outcomes — comparable to or exceeding behavioral interventions — would genuinely challenge Belief 2. If clinical intervention addresses the same outcomes attributed to "behavioral factors," the 80-90% attribution is more mutable than it appears.
What failure looks like: GLP-1 trial evidence remains too preliminary, effect sizes are small, or the mechanism is specific to metabolic/reward overlap rather than addiction broadly. This would confirm that Session 26's failed disconfirmation extends: biology matters at the mechanism level, but behavioral/environmental triggers remain primary.
Findings
Disconfirmation Attempt — Belief 2 (behavioral primacy): PARTIAL COMPLICATION
The central question: Do GLP-1s work across multiple "behavioral" conditions (obesity, alcohol, opioids, smoking) through a shared biological mechanism — and if so, does clinical intervention reclaim primacy from behavioral/environmental factors?
Verdict: Belief 2 is NOT overturned. But the evidence introduces a genuine structural complication that the 1993 behavioral primacy literature predates.
Finding 1: Semaglutide reduces alcohol consumption — Phase 2 RCT (Hendershot, JAMA Psychiatry 2025)
- Design: Phase 2, double-blind RCT; n=48, 9 weeks outpatient; non-treatment-seeking adults with AUD
- Primary outcomes: Lab self-administration (grams consumed, peak BrAC) + weekly drinking measures
- Results vs placebo:
- Lab self-administration: medium-large effects (β=−0.48 grams, β=−0.46 BrAC, both p<0.05)
- Heavy drinking days: significantly reduced (p=0.04)
- Drinks per drinking day: significant (β=−0.41, p=0.04)
- Weekly craving: significant (β=−0.39, p=0.01)
- Cigarettes per day in smokers: significant (p=0.005)
- Effect sizes: large (d>0.80) at weeks 5-8 (0.5 mg/week dose)
- Mechanism confirmed: VTA dopamine reward circuit suppression
- Limitations: n=48, non-treatment-seeking (moderate severity), Phase 2, 9 weeks only
Significance for Belief 2: This is the strongest RCT evidence that a clinical intervention (pharmacological) substantially reduces a "behavioral" outcome (alcohol consumption). The effects are large-range at therapeutic dose.
Finding 2: GLP-1 RA meta-analysis on alcohol — 14 studies (eClinicalMedicine 2025)
- Design: 14 studies (4 RCTs + 10 observational); n=5,262,278
- Pooled observational: HR 0.64 (95% CI 0.59–0.69) for alcohol-related events
- Pooled RCTs: SMD −0.24 (95% CI −0.70, 0.23) — non-significant pooled
- BUT: individual RCTs (Hendershot semaglutide, Probst dulaglutide) DO show significant results
- Non-significance from heterogeneity (I²=87.5%) and small samples, NOT absent effects
- AUDIT score reduction: −7.81 points (95% CI −9.02 to −6.60) — clinically meaningful
- Semaglutide and liraglutide identified as most effective agents
Key methodological note: The pooled RCT non-significance reflects heterogeneity and small-sample pooling issues — it does NOT mean the effects are absent. The Hendershot Phase 2 RCT with large effect sizes is the most reliable single-study evidence.
Finding 3: Qeadan 2025 — GLP-1 + OUD and AUD real-world outcomes (Addiction journal)
- Design: Retrospective cohort, 136 US health systems, >100M patient records (2014-2022)
- OUD cohort: 503,747 patients; 8,103 with GLP-1 RA prescriptions
- AUD cohort: 817,309 patients; 5,621 with GLP-1 RA prescriptions
- Opioid overdose: IRR 0.60 (95% CI 0.43–0.83) — 40% lower rate
- Alcohol intoxication: IRR 0.50 (95% CI 0.40–0.63) — 50% lower rate
- Consistent across T2DM, obesity, and comorbid subgroups
Caution on confounding: The healthy user bias concern is real — patients who can access/afford/tolerate GLP-1s may be healthier, more engaged with care, and have better outcomes for reasons unrelated to the GLP-1 mechanism. The authors used adjusted IRRs but retrospective observational data cannot rule this out. Treat as hypothesis-generating, not confirmatory.
Finding 4: GLP-1 + OUD — NO completed human RCT
- Phase 2 RCT protocol published (NCT06548490 — Penn State/Grigson): 200 participants, primary endpoint opioid abstinence on buprenorphine/methadone background, 12 weeks. Protocol published, trial NOT yet reported.
- Rodent models: GLP-1 RAs reduce opioid self-administration
- Real-world (Qeadan): 40% lower overdose, but observational
- Bottom line: OUD evidence is animal models + large-scale observational; no completed Phase 2 RCT
Finding 5: GLP-1 + Smoking — Mixed evidence
- Annals IM (real-world): semaglutide associated with significantly lower risk of tobacco use disorder encounters vs. other antidiabetics
- Phase 2 RCT (exenatide + NRT): increased abstinence vs placebo + NRT, reduced cravings, reduced post-cessation weight gain
- Phase 3 RCT ongoing: NCT05530577 (semaglutide 2.4mg vs placebo for smoking cessation, 177 participants)
- One RCT negative: dulaglutide + varenicline vs placebo + varenicline — no significant difference in abstinence (note: adding GLP-1 on top of already-effective varenicline may have ceiling effect)
- Bottom line: Promising but mixed. Real-world signal + one positive RCT + one null RCT.
OECD 2025 Data Confirmed: US preventable/treatable mortality split
- Preventable mortality: 217 per 100,000 (US) vs. 145 per 100,000 (OECD average) — 50% worse
- Treatable mortality: 95 per 100,000 (US) vs. 77 per 100,000 (OECD average) — 23% worse
- Life expectancy: 78.4 years, 2.7 years below OECD average
Note on prior session's data: Session 26 cited "4.3 years below peer-country average" — this appears to be comparing to specific peer countries (e.g. Japan, Switzerland), not the full OECD average (2.7 below). Both figures are directionally consistent. The 2.7 below OECD average is the most defensible citation.
The preventable/treatable split is the key evidence for Belief 2: the US underperforms far more on preventable mortality (conditions where behavior/environment is primary) than on treatable mortality (where clinical intervention is primary). US treatable mortality is only 23% worse; preventable mortality is 50% worse. Spending 2.5x the OECD average gives near-parity on clinical outcomes; preventable outcomes remain catastrophic.
Assessment of Belief 2 Disconfirmation
The disconfirmation attempt: PARTIAL COMPLICATION — NOT OVERTURNED
The GLP-1 reward-circuit story IS a genuine complication:
- A clinical intervention (semaglutide) produces medium-large effects on alcohol consumption, craving, and heavy drinking days
- The same mechanism extends (with weaker evidence) to opioids and smoking
- The biological substrate of "behavioral" conditions (reward dysregulation) is clinically accessible in a way the 1993 McGinnis-Foege framework didn't anticipate
But the disconfirmation fails at three levels:
- Evidence maturity: The AUD evidence is Phase 2 (n=48), 9 weeks. Population-scale evidence (Qeadan) is retrospective/observational. The meta-analytic RCT pooling is non-significant. This is not established clinical practice.
- Access applies equally: All the access barriers documented in Sessions 22-25 apply to GLP-1 for AUD: $1,000/month cost, coverage fragmentation, adherence cliff, access inversion. The drug works at the biological level; the structural failure doesn't care which condition it's treating.
- Mechanism vs. trigger remains: As Session 26 established for obesity — GLP-1 addresses the reward circuit mechanism; the behavioral/environmental factors (alcohol availability, social drinking norms, stress, economic despair) continue to activate the circuit. The trigger remains environmental/social.
New refined framing (CLAIM CANDIDATE):
"GLP-1 receptor agonists produce clinically meaningful reductions in alcohol consumption and craving through shared VTA dopamine reward circuit suppression — extending the same mechanism from metabolic disease to addiction and suggesting that 'behavioral' conditions have a biologically addressable substrate that 1990s health outcomes frameworks predated."
This is NOT a reversal of Belief 2. It is a qualification: the behavioral/clinical dichotomy is more porous than the original framework implied, specifically for reward-circuit conditions. Clinical intervention can address biological mechanisms underlying behavioral patterns — but it doesn't eliminate the behavioral/environmental triggers, and access barriers mean population-level impact remains constrained.
Confidence shift on Belief 2: Slight complication. The 80-90% attribution remains directionally correct, but the claim that "clinical care can only address 10-20%" is challenged at the mechanism level for reward-circuit conditions. The framing should shift from "clinical care addresses 10-20% of determinants" to "clinical care addresses mechanisms while behavioral/environmental interventions address triggers."
Follow-up Directions
Active Threads (continue next session)
- CLAIM CANDIDATE: GLP-1 reward circuit claim: Draft the claim about shared VTA dopamine mechanism across obesity, AUD, and (provisionally) OUD. Evidence: Hendershot JAMA Psychiatry 2025 (AUD RCT), Qeadan 2025 (real-world), mechanistic literature. Confidence: experimental (Phase 2 evidence, mechanism confirmed, observational support). This is ready to draft but needs careful scope qualification.
- Clinical AI deskilling/upskilling divergence file: Still overdue. All evidence is in queue (PMC11780016, Oettl 2026, scoping review, colonoscopy RCT, pathology never-skilling). Next session: CREATE this file. No more deferrals.
- OECD preventable mortality claim: The US 217 vs. 145/100K preventable mortality gap (50% worse) needs to be in the KB. Either new claim or enrichment of existing SDOH/epidemiological transition claims. Data is confirmed from OECD 2025.
- Provider consolidation claim — execute: GAO-25-107450 + HCMR 2026 evidence is sitting in queue. The qualified claim is ready to draft and PR.
- GLP-1 OUD RCT results (NCT06548490 — Penn State): Monitor for results. 200 participants, 12 weeks. Protocol published. If this shows significant OUD outcomes, the reward-circuit claim strengthens from "experimental" toward "likely."
Dead Ends (don't re-run these)
- GLP-1 RCT pool for AUD as definitive evidence: The pooled meta-analytic RCT result is non-significant due to small-sample heterogeneity. The individual Hendershot RCT is the strongest evidence; searching for a larger pooled RCT dataset won't find one — Phase 3 trials are only now starting.
- Dulaglutide for smoking cessation: One null RCT (dulaglutide + varenicline). The ceiling effect with varenicline makes this uninformative about GLP-1 mechanism for smoking.
Branching Points (today's findings opened these)
- Belief 2 reframe: Direction A (write the "behavioral/clinical dichotomy is false: clinical intervention addresses mechanism, behavioral/environmental intervention addresses trigger" as a theoretical framing claim) vs. Direction B (wait for stronger clinical evidence before complicating Belief 2). Pursue Direction A — the theoretical contribution is ready even if the full clinical evidence isn't. The OECD data confirms Belief 2 at the population level; the GLP-1 data qualifies it at the mechanism level. Both can be true.
- GLP-1 reward circuit cross-domain: The addiction medicine finding has cross-domain implications. Clay connection: if addiction is a biologically-mediated reward circuit condition, narrative infrastructure's role becomes about maintaining access to environments that don't continuously trigger the circuit — not about willpower. Theseus connection: VTA dopamine reward circuits may be relevant to understanding AI behavioral influence (persuasion, engagement design).